Key statistics
On Wednesday, Inhibikase Therapeutics Inc (IKT:NAQ) closed at 1.26, 59.49% above the 52 week low of 0.79 set on Oct 10, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.52 |
---|---|
High | 1.88 |
Low | 1.15 |
Bid | 1.21 |
Offer | 1.25 |
Previous close | 1.19 |
Average volume | 12.22k |
---|---|
Shares outstanding | 7.46m |
Free float | 6.57m |
P/E (TTM) | -- |
Market cap | 8.88m USD |
EPS (TTM) | -2.93 USD |
Data delayed at least 15 minutes, as of Oct 09 2024 21:00 BST.
More ▼
Announcements
- Inhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial Hypertension
- Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity
- Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024
- Inhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201’ Trial Evaluating Risvodetinib in Untreated Parkinson’s Disease
- Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs
- Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million
- Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity
- Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement
- Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension
- Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
More ▼